Navigating the shift to next-generation propellants in pMDIs by balancing environmental goals, patient care, and regulatory demands.
cRespiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK dRespiratory and Immunology, Clinical Development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results